Grey Street Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

Grey Street Capital’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$746K	Buy	+50,820	New	+$742K	0.1%	229

Other funds holding RDY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Grey Street Capital's RDY Position: Q1 2024 in Review

Grey Street Capital opened a new position in Dr. Reddy's Laboratories (RDY) in Q1 2024: 50,820 shares worth $746K. The stake represents 0.1% of the portfolio and ranks #229 among its holdings.

231 funds tracked by Wall St. Rank hold RDY as of Q1 2024.

Grey Street Capital held 50,820 shares of Dr. Reddy's Laboratories worth $746K as of Q1 2024.
Dr. Reddy's Laboratories was a new Grey Street Capital position in Q1 2024.
Dr. Reddy's Laboratories made up 0.1% of Grey Street Capital's portfolio in Q1 2024, its #229 holding.
231 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2024.

Based on Grey Street Capital's 13F filing for Q1 2024, filed 9 Aug 2024.